HP
HRMY icon

HealthInvest Partners’s Harmony Biosciences HRMY Stock Holding History

HealthInvest Partners’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-92,074
Closed -$269K – 41
2025
Q3 		$269K Buy
92,074
+5,800
+7% +$200K 1% 30
2025
Q2 		$2.73M Sell
86,274
-5,027
-6% -$162K 1.17% 28
2025
Q1 		$3.03M Sell
91,301
-29,200
-24% -$1.05M 1.34% 23
2024
Q4 		$4.1M Sell
120,501
-31,374
-21% -$1.08M 1.95% 17
2024
Q3 		$6.08M Buy
151,875
+116,975
+335% +$4.11M 2.86% 15
2024
Q2 		$1.05M Sell
34,900
-135,100
-79% -$4.06M 0.64% 31
2024
Q1 		$5.71M Buy
170,000
+25,000
+17% +$802K 3.47% 6
2023
Q4 		$4.68M Buy
+145,000
New +$4.05M 3.67% 8
2022
Q3 		– Sell
-76,000
Closed -$3.71M – 12
2022
Q2 		$3.71M Sell
76,000
-44,000
-37% -$1.98M 8.55% 3
2022
Q1 		$5.84M Sell
120,000
-75,000
-38% -$3.06M 9.3% 5
2021
Q4 		$8.31M Buy
195,000
+10,000
+5% +$399K 11.72% 3
2021
Q3 		$7.09M Buy
+185,000
New +$5.96M 10.62% 4

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HealthInvest Partners's HRMY Position: Q4 2025 in Review

HealthInvest Partners sold out of Harmony Biosciences (HRMY) in Q4 2025, closing a stake of 92,074 shares — an estimated $269K sold.

HealthInvest Partners first reported a position in HRMY in Q3 2021 and held it in 12 quarters. The position peaked at $8.31M in Q4 2021. 323 funds tracked by Wall St. Rank hold HRMY as of Q4 2025.

  • HealthInvest Partners reported no remaining Harmony Biosciences position as of Q4 2025 after selling out during the quarter.
  • HealthInvest Partners sold 92,074 Harmony Biosciences shares in Q4 2025, an estimated $269K.
  • HealthInvest Partners first reported a position in Harmony Biosciences in Q3 2021 and held it in 12 quarters.
  • HealthInvest Partners's Harmony Biosciences position peaked at $8.31M in Q4 2021.
  • 323 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2025.

Based on HealthInvest Partners's 13F filing for Q4 2025, filed 6 Feb 2026.